Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
To find out patent expiration data for the Czech Republic
— Doctor, Czech Republic
To get information on drug patent expirations for the UK
— Commercial analyst, UK
To apply for a patent
— Pharmaceutical researcher, USA
To know more about patents of drug products and drug substances
— Manager, formulation R&D, India
To prepare patent landscapes and give IP clearance for APIs
— Analyst, India
Generated: May 25, 2017
Which patents cover Alecensa, and when can generic versions of Alecensa launch?
Alecensa is a drug marketed by Hoffmann-la Roche and is included in one NDA. There are three patents protecting this drug.| Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: see list | 1 |
| Bulk Api Vendors: see list | 45 |
| Clinical Trials: see list | 2 |
| Patent Applications: see list | 2 |
| Drug Prices: | see details |
| DailyMed Link: | ALECENSA at DailyMed |
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Kinase Inhibitors |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | 9,365,514 | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | ► Subscribe | ► Subscribe | |||||||||||||||||||
Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | 9,440,922 | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | 9,126,931 | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Hoffmann-la Roche | ALECENSA | alectinib hydrochloride | CAPSULE;ORAL | 208434-001 | Dec 11, 2015 | RX | Yes | Yes | ► Subscribe | ► Subscribe | |||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Expired Orange Book Patents
Available with subscription
Paragraph IV Activity
Available with subscription
Patent Maintenance
Available with subscription
Non-Orange Book Patents
Available with subscription
International Patents
Available with subscription
Supplementary Protection Certificates
Available with subscription
To track filing and history of various APIs
— API research and development, USA
To know what drugs are coming off patent over the next 5 years
— CRO business development manager, USA
To get patent expiration dates and find out when generics plan to advertise and enter the market
— Pharmacist, USA
To determine when a drug loses patent protection in the United States
— Medical consultant, USA
To study crossover potential for veterinary medicine
— Chief medical officer, USA
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
